4baseCare Accelerates Global Precision Oncology with $13.4 Million Funding
June 12, 2026, 9:33 am
Precision oncology leader 4baseCare secured $13.4M in Series B funding. This capital fuels global genomics lab expansion and scales OncoTwin, its AI platform. The company targets diverse populations, decentralizing cancer diagnostics. It aims for accessible, personalized treatment, addressing critical data gaps worldwide.
Bengaluru-based 4baseCare leads precision oncology innovation. The startup recently closed its Series B funding round. It secured an additional Rs 38 crore, equivalent to nearly $4 million. This top-up brings its total Series B raise to Rs 128 crore. That sum translates to approximately $13.4 million.
New and existing investors fueled this significant capital injection. GrowX Ventures led the extended round. Veteran investors Ashish Kacholia and Lashit Sanghvi co-led an earlier Rs 90 crore tranche. Existing backer Yali Capital also participated. Infosys notably joined the round, highlighting a strategic investment in healthcare AI.
4baseCare emerged in 2018. Hitesh Goswami and Kshitij Rishi founded it. They envisioned a future where cancer care is highly personalized. Their mission addresses critical gaps in population-relevant genomic data. The company combines advanced genomic testing with AI-powered clinical intelligence. This synergy enables more effective, tailored cancer treatment strategies.
The fresh capital has a clear purpose. 4baseCare plans aggressive geographic expansion. It targets a global genomics lab network. Key regions include India, the Middle East, Southeast Asia, Latin America, and Central Asia. This expansion enhances access to cutting-edge cancer diagnostics. It democratizes precision oncology.
Scaling its tech platform OncoTwin is another core objective. OncoTwin is an AI-based precision oncology platform. It leverages multimodal datasets. These include genomic, pathology, radiology, and clinical information. OncoTwin creates "digital twins" of cancer patients. It matches them with similar treatment journeys. This provides doctors with real-world evidence. It guides informed clinical decisions.
A major challenge in precision oncology is data imbalance. Genomic datasets predominantly feature Caucasian populations. This limits relevance for diverse global communities. 4baseCare directly confronts this issue. It builds genomics infrastructure in underrepresented regions. It develops clinically contextualized data. Its AI-driven intelligence fills this critical gap. The company champions inclusive precision oncology worldwide.
Decentralization forms a key domestic strategy. 4baseCare is expanding its genomics laboratory network across India. It partners with major healthcare providers. Max Healthcare, AIIMS Jammu, and Shankara Hospital are among them. This initiative establishes in-hospital genomics labs. It moves technology closer to patients and doctors. This approach dramatically improves diagnostic turnaround times. It fosters research collaboration. It makes advanced cancer diagnostics more accessible beyond major metros.
Currently, 4baseCare operates four active labs in India. It conducts around 1,500 genomic tests monthly. The planned expansion aims for massive scaling. Testing volumes could reach 8,000-10,000 tests per month. This growth directly addresses India's substantial cancer burden. The nation sees nearly 1.5 million new cancer cases annually. A high percentage, about 70%, are diagnosed at advanced stages. Genomic testing is vital for these patients. It identifies molecular changes in tumors. It maps patients to targeted therapies and immunotherapies.
Cancer treatment has evolved significantly. Chemotherapy once dominated. Now, genomics and biomarkers drive highly targeted approaches. 4baseCare contributes to this evolution. Its solutions facilitate precise remedies. The company also focuses on affordability. It has lowered prices for its offerings. Some solutions cost one-fourth of competitors. The ultimate goal involves integration into public healthcare schemes like Ayushman Bharat. This would make genomic testing universally accessible.
Precision oncology represents a rapidly growing healthcare AI segment. Hospitals and pharmaceutical companies increasingly utilize genomic and clinical data. They personalize cancer treatment strategies. 4baseCare is at the forefront of this trend. Its OncoTwin platform offers a sophisticated solution. It provides invaluable insights without recommending direct treatments. It empowers doctors with data-driven confidence.
Infosys's investment underscores 4baseCare's strategic value. Infosys recognizes 4baseCare as more than a diagnostics company. It builds AI solutions on healthcare datasets. This aligns with Infosys's broader healthcare and AI initiatives. Infosys expands its health tech footprint globally. It invests in healthcare data and AI-focused enterprises. 4baseCare fits this strategic vision perfectly.
The startup has proven its financial viability. It has been revenue positive for five years. Current annual revenues stand at approximately Rs 40 crore. Aggressive growth targets are set. The company expects to cross Rs 100 crore in annual revenues within 12-18 months. This robust financial performance reinforces investor confidence. It validates its market strategy.
4baseCare continues its mission. It transforms cancer care. It makes personalized treatment accessible worldwide. Its expanded funding and AI platform drive this future. The company builds a healthier, more equitable future for oncology.
Bengaluru-based 4baseCare leads precision oncology innovation. The startup recently closed its Series B funding round. It secured an additional Rs 38 crore, equivalent to nearly $4 million. This top-up brings its total Series B raise to Rs 128 crore. That sum translates to approximately $13.4 million.
New and existing investors fueled this significant capital injection. GrowX Ventures led the extended round. Veteran investors Ashish Kacholia and Lashit Sanghvi co-led an earlier Rs 90 crore tranche. Existing backer Yali Capital also participated. Infosys notably joined the round, highlighting a strategic investment in healthcare AI.
4baseCare emerged in 2018. Hitesh Goswami and Kshitij Rishi founded it. They envisioned a future where cancer care is highly personalized. Their mission addresses critical gaps in population-relevant genomic data. The company combines advanced genomic testing with AI-powered clinical intelligence. This synergy enables more effective, tailored cancer treatment strategies.
The fresh capital has a clear purpose. 4baseCare plans aggressive geographic expansion. It targets a global genomics lab network. Key regions include India, the Middle East, Southeast Asia, Latin America, and Central Asia. This expansion enhances access to cutting-edge cancer diagnostics. It democratizes precision oncology.
Scaling its tech platform OncoTwin is another core objective. OncoTwin is an AI-based precision oncology platform. It leverages multimodal datasets. These include genomic, pathology, radiology, and clinical information. OncoTwin creates "digital twins" of cancer patients. It matches them with similar treatment journeys. This provides doctors with real-world evidence. It guides informed clinical decisions.
A major challenge in precision oncology is data imbalance. Genomic datasets predominantly feature Caucasian populations. This limits relevance for diverse global communities. 4baseCare directly confronts this issue. It builds genomics infrastructure in underrepresented regions. It develops clinically contextualized data. Its AI-driven intelligence fills this critical gap. The company champions inclusive precision oncology worldwide.
Decentralization forms a key domestic strategy. 4baseCare is expanding its genomics laboratory network across India. It partners with major healthcare providers. Max Healthcare, AIIMS Jammu, and Shankara Hospital are among them. This initiative establishes in-hospital genomics labs. It moves technology closer to patients and doctors. This approach dramatically improves diagnostic turnaround times. It fosters research collaboration. It makes advanced cancer diagnostics more accessible beyond major metros.
Currently, 4baseCare operates four active labs in India. It conducts around 1,500 genomic tests monthly. The planned expansion aims for massive scaling. Testing volumes could reach 8,000-10,000 tests per month. This growth directly addresses India's substantial cancer burden. The nation sees nearly 1.5 million new cancer cases annually. A high percentage, about 70%, are diagnosed at advanced stages. Genomic testing is vital for these patients. It identifies molecular changes in tumors. It maps patients to targeted therapies and immunotherapies.
Cancer treatment has evolved significantly. Chemotherapy once dominated. Now, genomics and biomarkers drive highly targeted approaches. 4baseCare contributes to this evolution. Its solutions facilitate precise remedies. The company also focuses on affordability. It has lowered prices for its offerings. Some solutions cost one-fourth of competitors. The ultimate goal involves integration into public healthcare schemes like Ayushman Bharat. This would make genomic testing universally accessible.
Precision oncology represents a rapidly growing healthcare AI segment. Hospitals and pharmaceutical companies increasingly utilize genomic and clinical data. They personalize cancer treatment strategies. 4baseCare is at the forefront of this trend. Its OncoTwin platform offers a sophisticated solution. It provides invaluable insights without recommending direct treatments. It empowers doctors with data-driven confidence.
Infosys's investment underscores 4baseCare's strategic value. Infosys recognizes 4baseCare as more than a diagnostics company. It builds AI solutions on healthcare datasets. This aligns with Infosys's broader healthcare and AI initiatives. Infosys expands its health tech footprint globally. It invests in healthcare data and AI-focused enterprises. 4baseCare fits this strategic vision perfectly.
The startup has proven its financial viability. It has been revenue positive for five years. Current annual revenues stand at approximately Rs 40 crore. Aggressive growth targets are set. The company expects to cross Rs 100 crore in annual revenues within 12-18 months. This robust financial performance reinforces investor confidence. It validates its market strategy.
4baseCare continues its mission. It transforms cancer care. It makes personalized treatment accessible worldwide. Its expanded funding and AI platform drive this future. The company builds a healthier, more equitable future for oncology.